Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) CFO Nicholas Smith sold 110,830 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total value of $2,945,861.40. Following the completion of the transaction, the chief financial officer owned 24,060 shares in the company, valued at approximately $639,514.80. This represents a 82.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Nicholas Conrad Smith also recently made the following trade(s):
- On Wednesday, September 30th, Nicholas Smith sold 24,056 shares of Alto Neuroscience stock. The shares were sold at an average price of $25.82, for a total transaction of $621,125.92.
Alto Neuroscience Stock Performance
ANRO opened at $24.77 on Friday. Alto Neuroscience, Inc. has a 1-year low of $4.71 and a 1-year high of $37.48. The company has a market cap of $972.05 million, a price-to-earnings ratio of -10.24 and a beta of 1.31. The company’s fifty day moving average price is $31.09 and its two-hundred day moving average price is $26.14. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07.
Hedge Funds Weigh In On Alto Neuroscience
Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in shares of Alto Neuroscience by 18.6% in the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock worth $1,871,000 after buying an additional 11,114 shares in the last quarter. AWM Investment Company Inc. purchased a new position in Alto Neuroscience during the second quarter valued at approximately $2,111,000. Bank of New York Mellon Corp purchased a new stake in Alto Neuroscience in the 2nd quarter worth approximately $2,014,000. GK Wealth Management LLC purchased a new stake in Alto Neuroscience in the 2nd quarter worth approximately $226,000. Finally, Perceptive Advisors LLC boosted its holdings in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares during the period.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the company. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Wedbush boosted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. BTIG Research upped their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.
Check Out Our Latest Analysis on ANRO
Alto Neuroscience Company Profile
Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.
Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
